Form 4: Zura Bio CFO Granted Significant Stock Options

Zura Bio Ltd's Chief Financial Officer, Eric J. Hyllengren, was granted 672,000 employee share options with a vesting schedule tied to continuous service.

Summary

• Eric J. Hyllengren, Chief Financial Officer of Zura Bio Ltd (ZURA), reported the acquisition of derivative securities.
• He was granted 672,000 employee share options.
• The exercise price for these options is $1.3 per Class A Ordinary Share.
• The transaction date for the option grant was July 15, 2025.
• The options have an expiration date of July 15, 2035.
• The vesting schedule for the options is as follows: one-fourth (1/4th) of the shares subject to the option award shall vest on July 7, 2026, and one-twelfth (1/12th) of the remaining shares shall vest in equal quarterly installments thereafter, contingent upon the Reporting Person's continuous service through each vesting date.
• Following this reported transaction, Eric J. Hyllengren beneficially owns 672,000 derivative securities (employee share options).

Sentiment

Score: 7

Explanation: The grant of significant stock options to a key executive like the CFO is generally viewed positively as it aligns management's interests with shareholders and incentivizes long-term performance and retention. It is a standard compensation practice.

Positives

• The grant of 672,000 employee share options to the Chief Financial Officer aligns management's long-term interests with those of shareholders, incentivizing performance and retention.
• The substantial number of options indicates a significant commitment to the executive's role and potential future contributions to the company's success.

Future Outlook

The vesting schedule for the employee share options extends over several years, with the first tranche vesting in July 2026 and subsequent quarterly installments, indicating a long-term incentive structure designed to retain the Chief Financial Officer and align his performance with the company's future growth.

Industry Context

The granting of stock options to key executives is a common and standard practice across various industries, including biotechnology, serving as a crucial component of executive compensation packages. This strategy aims to attract, retain, and incentivize top talent by aligning their financial interests with the long-term performance and shareholder value creation of the company.

Comparison to Industry Standards

• Granting stock options to executives is a standard compensation practice across industries, including the biotechnology sector, to incentivize long-term performance.
• The multi-year vesting schedule (1/4th initially, then quarterly installments of the remainder) is a typical structure for executive incentive plans, designed to ensure continuous service and align interests over an extended period.
• The specific number of options (672,000) is significant and would be evaluated against the company's market capitalization, stage of development, and peer group compensation practices to determine its relative scale, though the document does not provide such comparative data.

Related Party Transactions

• Grant of 672,000 employee share options to Eric J. Hyllengren, the Chief Financial Officer, as part of his compensation package.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of the Chief Financial Officer's interests with long-term shareholder value creation and company performance.
• Employees: No direct impact on general employees is mentioned, but the grant highlights the company's executive compensation strategy and commitment to retaining key leadership.

Next Steps

• The vesting of the employee share options will occur in installments, with the first quarter (1/4th) vesting on July 7, 2026, and subsequent quarterly installments of 1/12th of the remaining shares, subject to continuous service.

Key Dates

Keywords

Zura Bio Ltd, ZURA, SEC Form 4, stock options, employee share options, executive compensation, Eric J Hyllengren, Chief Financial Officer, insider transaction, beneficial ownership